Schering-Plough 2% Gyne-Lotrimin 3 Cream Will Be Launched In February
This article was originally published in The Tan Sheet
Executive Summary
A new dosage form of Schering-Plough's vaginal yeast infection treatment Gyne-Lotrimin 3 with a 2% dose of the active ingredient clotrimazole will be introduced by the company in February. Schering plans no major advertising but will undertake FSIs.
You may also be interested in...
Private Label Three-Day Yeast Infection Cream Offered By Taro
Taro Pharmaceutical Industries' new drug application for clotrimazole 2% three-day cream was approved April 14 as a private label OTC vaginal yeast infection treatment identical to Schering-Plough's Gyne-Lotrimin 3 Cream. The product will appear on store shelves of major chains and mass merchandisers beginning in May.
Private Label Three-Day Yeast Infection Cream Offered By Taro
Taro Pharmaceutical Industries' new drug application for clotrimazole 2% three-day cream was approved April 14 as a private label OTC vaginal yeast infection treatment identical to Schering-Plough's Gyne-Lotrimin 3 Cream. The product will appear on store shelves of major chains and mass merchandisers beginning in May.
Private Label Three-Day Yeast Infection Cream Offered By Taro
Taro Pharmaceutical Industries' new drug application for clotrimazole 2% three-day cream was approved April 14 as a private label OTC vaginal yeast infection treatment identical to Schering-Plough's Gyne-Lotrimin 3 Cream. The product will appear on store shelves of major chains and mass merchandisers beginning in May.